Gene therapy has suffered another disappointment. Temusi, the Vical candidate partnered with Sanofi-Aventis that aimed to regrow arteries in patients with critical limb ischaemia (CLI), failed to prevent amputation or death when compared to placebo over 12 months of follow-up in a phase III trial.The likely loss of Temusi caused Vical's shares to fall 32% Wednesday to a 12-month low of $2.62, amid disappointment that the company's most advanced product, partnered with a major global company, has failed to live up to its promise. Vical will lose out on milestones and royalties on sales projected at $115m in 2016, making its loss a significant blow.
This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions
Follow us on Twitter